Article info

Download PDFPDF
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

Authors

  1. Address correspondence and reprint requests to: Thomas G. Ehlen, MD, Vancouver Cancer Center, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. Email: tehlen{at}vanhosp.bc.ca

Citation

EHLEN TG, HOSKINS PJ, MILLER D, et al
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

Publication history

  • First published November 1, 2005.
Online issue publication 
February 26, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.